Products for the Treatment of Factor VIII Deficiency



Similar documents
Bayer HealthCare, LLC Sharps Disposal Submission to CalRecycle July 1, 2014

Reconstitution of Solutions

Medications or therapeutic solutions may be injected directly into the bloodstream

Ward 29 guide to the safe preparation and administration of intravenous (IV) antibiotics at home

PASSP RT. to well-being CHARTING YOUR COURSE. empowering people with bleeding disorders to maximize their quality of life

Chapter 15. Reconstitution and Dosages Measured in Units. Copyright 2012, 2007 Mosby, Inc., an affiliate of Elsevier Inc. All rights reserved.

Promoting safer use of injectable medicines

GAO MEDICARE. Payment for Blood Clotting Factor Exceeds Providers Acquisition Cost

I-140 Venipuncture for Blood Specimen Collection

Insulin and Diabetes

NIH Clinical Center Patient Education Materials Giving a subcutaneous injection

Treatment of Hemophilia A and B Marianne McDaniel, RN FACTOR REPLACEMENT CONCENTRATES AND VIRAL INACTIVATION

Good practice for the preparation of injectable medicines in clinical areas

How To Store An Acam2000 Vaccine

HIGHLIGHTS OF PRESCRIBING INFORMATION

INJECTION TECHNIQUE. IVF NURSING OFFICE: (301) Darshana (301) Nicole

For Educational Use Only - Not for Detailing or Distribution

RECONSTITUTING MEDICATIONS: HOW TO FLUFF UP MEDICATIONS

IVF CLASS. IVF NURSE CONTACT INFORMATION: Darshana , Nicole ,

Humulin R (U500) insulin: Prescribing Guidance

Administration of Meropenem For Child

MEDICATION GUIDE (ex tā vee uh) What is the most important information I should know about EXTAVIA?

Annex I. Article 31 of Directive 2001/83/EC. Procedure number: EMEA/H/A-31/1448

intervals. More frequent or higher doses up to 80 IU/kg may be required in children less than 6 years of age. (2)

Instructions for Use PROCRIT (PRO KRIT) (epoetin alfa)

2016 PHARMACY. Benefit Summary Book. RXSUMBK2016

Using a Graseby MS26 Syringe Driver for Continuous Subcutaneous Infusions (CSCI) Protocol

International Student Health Insurance Program (ISHIP)

ADMINISTRATION OF INTRAVENOUS PUSH/DIRECT MEDICATIONS

Giving Yourself Dalteparin (Fragmin) or Heparin

Illinois Valley Community College Nursing Program Math Questions

Prescription Drug Plan

INSULINThere are. T y p e 1 T y p e 2. many different insulins for

Administration of Medications & Fluids via a Peripheral Intravenous Cannula

Policy and Procedure Flushing and / or Blood withdrawal Aspiration Procedure For PICC Line and Midline Catheters

How Is OnabotulinumtoxinA Reimbursed For Chronic Migraine? Impact Of FDA Approval And The New CPT Code

SUBMISSION ON THE FUNDING OF EXTENDED HALF LIFE FACTOR VIII CONCENTRATES

welcome to 2016 Annual Enrollment! OCTOBER 15 NOVEMBER 18, 2015

Field Report Field Report Field Report Field Report Field Report

PROCEDURE FOR SUBCUTANEOUS INSERTION, REMOVAL, MEDICATION ADMINISTRATION AND FLUID ADMINISTRATION FOR COMMUNITY PALLIATIVE CARE PATIENTS

POSSIBLE NURSING DIAGNOSIS: Pain Potential for Infection / Infection Fluid volume deficit

FREQUENTLY ASKED QUESTIONS (FAQ)

Needlestick Injury Prevention Assessment Tool

Insulin T Y P E 1 T Y P E 2

Equipment and Supplies

Flexible Blue SM Plan 2 Medical Coverage with Flexible Blue SM RX Prescription Drugs Benefits-at-a-Glance for Western Michigan Health Insurance Pool

FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM

Heart problems - What are the possible side effects of AVONEX? What is AVONEX? Who should not take AVONEX?

CHAPTER 6 OUTPATIENT SURGICAL CENTERS 6. 1

Your Specialty Medication Handbook

Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended. (1) by striking clause (ii) and inserting the following:

Date effective: Jan 2005 Date revised: June 2015

Position Classification Standard for Pharmacy Technician Series, GS-0661

Go to to access the Plan Finder HOW TO USE THE MEDICARE.GOV PART D PRESCRIPTION DRUG PLAN FINDER

Care for your child s Central Venous Catheter (CVC)

Blue Cross Blue Shield of Michigan

Outpatient Prescription Drug Benefit

scriptsourcing THE NEXT 5 YEARS OF RX COSTS AND HOW THEY WILL IMPACT YOUR BOTTOM LINE ScriptSourcing Prescription Advocacy Services

Recommendations for the Safe Use of Handling of Cytotoxic Drugs

PRODUCT RETURN POLICY

CMP Antibody Production Service

The OmniPod Insulin Management System

To maintain a port of entry to venous flow when all available peripheral ports have failed.

New York City Office of Labor Relations Employee Benefits Program/Municipal Labor Committee

BEAUMONT HOSPITAL DEPARTMENT OF NEPHROLOGY RENAL BIOPSY

My Doctor Says I Need to Mix Insulins... How Do I Begin? BD Getting Started. Mixing Insulins

Instructions for Use

HEALTH CARE DENTAL CARE

KwikPen Insulin delivery device

2006 Provider Coding/Billing Information.

Your Summary of Benefits PPO Copay Plans

GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS

INSTITUTIONAL POLICY AND PROCEDURE (IPP) Department: Manual: Section: EFFECTIVE DATE REVIEW DUE REPLACES NUMBER NO. OF PAGES

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

IN THIS ISSUE. Formulating Happiness. Functional Excipients. OraGuardTM Technology. Atorvastatin ER Tablets. Protecting Intended Action

EMPLOYER BASED QUALIFIED PHARMACY TECHNICIAN EXAMS GUIDANCE

STATE 340B MEDICAID BILLING BEST PRACTICES

Safe Medication Administration Preparation Guide C.O.R.E Essentials

Subject: Unit Dose PLUS Outsource Re-Packaging Service from Healthmark

UW School of Dentistry Comprehensive Medication Policy

Patient Information Guide Morpheus CT Peripherally Inserted Central Catheter

Reliability and predictable costs for individuals and families

PATIENT INFORMATION. Medicine To Treat: D iabetes. What You Need to Know About. Insulin

BROCKTON AREA MULTI-SERVICES, INC. MEDICAL PROCEDURE GUIDE. Date(s) Reviewed/Revised:

New York Small Group Indemnity Aetna Life Insurance Company Plan Effective Date: 10/01/2010. PLAN DESIGN AND BENEFITS - NY Indemnity 1-10/10*

Caring for a Tenckhoff Catheter

Healthcare Observer Jan 2013

Self-Assessment Questions

National Patient Safety Agency. Risk Assessment of Injectable Medicines. STEP 1 Local Risk Factor Assessment. STEP 2 Product Risk Factor Assessment

TITLE CLIN_216 HEMODIALYSIS/PLASMAPHERESIS PROCEDURE AND CATHETER MANAGEMENT FOR THE ADULT AND PEDIATRIC PATIENT

Dickinson Wright, PLLC

WellDyneRx Mail Service General Questions and Answers

SAFE HANDLING OF HAZARDOUS MEDICATIONS. Cytotoxic and Non-Cytotoxic. Winnipeg Regional Health Authority Policy #

Verbalize knowledge of laws and policies for administration of prescribed and over the counter medication to students.

X-Plain Subclavian Inserted Central Catheter (SICC Line) Reference Summary

Dot Blot Analysis. Teacher s Guidebook. (Cat. # BE 502) think proteins! think G-Biosciences

Syringe. Product Usage Information: Precautions:

Specialty drug program. Save time. Save money. Feel good.

INTRAVENOUS DRUG QUICKGUIDE

YOUR GUIDE TO THE LANTUS SOLOSTAR INSULIN PEN

Transcription:

Products for the Treatment of Factor VIII Deficiency Conference Call August 24, 2004 7pm-8pm Presenters: Marcus E. Carr, MD, PhD & Gita V. Massey, MD I. Overview of Factor VIII products currently on the market Advate (Baxter) Helixate FS (ZLB Behring) Kogenate FS (Bayer) ReFacto (Wyeth) Recombinate (Baxter) II. Thoughts to consider when choosing a factor product Cost Infusion III. Question and answer time This program is brought to you to with support from Hemophilia Health Services, a specialty homecare pharmacy that serves the bleeding disorders community.

Factor VIII Products Comparison Chart Advate Helixate FS Kogenate FS ReFacto Recombinate (Third generation) (Second generation) (Second generation) (Second generation) (First generation) Distributor Baxter Bioscience ZLB Behring Bayer Corporation *86% good/excellent *80-90% excellent/good *80-90% excellent/ good Efficacy response rate (100% in response rate (100% for response rate (100% for surgeries) surgeries) surgeries) Wyeth *92% excellent/good response rate Baxter Bioscience *92-95% excellent/good response rate Studies *No PUP studies *PUP and PTP *PUP and PTP *PUP and PTP *PUP and PTP Half-Life 11.98 +/- 4.28 hours 13.3 +/- 1.6 hours 13.3 +/- 1.6 hours 14.5 +/-5.3 hours 14.6 +/- 4.9 hours Inhibitors No PUP studies; no inhibitors in patients under 6 years 16% in PUP studies 16% in PUP studies 30% in PUP studies 32% in PUP studies Safety MAIC** Exposure to Human Albumin Vial Ranges None; uses a sugar (trehalose) as stabilizer 250, 500, 1000, 1500 IU MAIC** and solvent detergent MAIC** and solvent detergent Uses albumin in Uses albumin in fermentation; no albumin in fermentation; no albumin final form; sugar (sucrose) in final form; sugar as stabilizer (sucrose) as stabilizer MAIC** Uses albumin in fermentation; no albumin in final form; sugar (sucrose) as stabilizer 250, 500, 1000 IU 250, 500, 1000 IU 250, 500, 1000 1500, 2000 IU MAIC** Uses human albumin and bovine protein as stabilizers 250, 500, 1000 IU Reconstituted Volume 5 ml 2.5 ml 2.5 ml 4 ml 10 ml Storage Refrigeration or room temp for 6 months Peel off label Refrigeration Refrigeration Refrigeration or Refrigeration or room temp for 6 months room temp Peel off label Peel off label Peel off label Other Features Butterfly needle included Letter coded packaging Butterfly needle included Color coded packaging Butterfly needle included Color coded packaging Butterfly needle included Color coded packaging Color coded packaging * PUP- Previously Untreated Patients; PTP- Previously Treated Patients ** MAIC- Monoclonal antibody immunoaffinity chromography

CONSIDERATIONS WHEN CHOOSING A FACTOR PRODUCT: COST I. Cost of factor to the family is determined by several factors: 1. Co-pays dictated by insurance a. Some carriers require a percent of cost co-pay to the family for every order of factor concentrate; b. More expensive products would therefore lead to higher costs for families; c. Some home infusion companies will consider financial waivers for co-pays or will work with a third party to waive or reduce co-pays. 2. Insurance formularies a. Some insurance companies cover only certain medications on their routine medication list. Those medications not on the list may be more expensive or not covered. b. Some insurance companies require special authorization for more expensive medications and may limit the amount of medication available at a time. 3. Insurance caps a. Some insurance carriers have a ceiling or maximum amount that they will pay for a patient for their lifetime. Lifetime caps can be expended more quickly for more expensive medications. II. Cost of factor to the insurance company is determined by several factors: 1. Average wholesale price of the medication a. Affected by manufacturer s pricing 2. Contractual agreements between home infusion companies and insurance companies a. Based on size of company, partnerships with manufacturer etc

Questions to ask your home infusion company when selecting a factor product: 1. What is the cost per unit charged to your insurance company of the factor concentrate that you are currently using? 2. What is the cost per unit of the factor concentrate that you are considering? Recall that different home infusion companies may charge different prices for the same product. However, some companies will charge less for a unit of factor, but bill for every ancillary supply (needles, syringes, port supplies, Sharps container) and for nursing services not covered by insurance. 3. Can your home care company obtain the factor concentrate that you desire in the assays that you need? Remember that using assays (number of units in a vial) that are much larger than what you need can dramatically increase the cost of the infusion of factor concentrate. For example, if your prescribed dose is 750 units, but you can only get 900 unit vials, you are being charged for the extra 150 units of factor that you may not need. Questions to ask your insurance company when selecting a factor product: 1. Do you have a lifetime cap on your insurance policy? If so, how much have you used toward the cap? Many insurance policies have a lifetime cap (limit) for payments, meaning there is a maximum amount the policy will pay for an individual. Once the policy has reached this limit, the patient caps out, meaning their insurance company will no longer pay for coverage. 2. Which home infusion companies are covered on your policy? Insurers contract with home infusion companies to provide factor. Some insurance policies may allow patients to choose between several companies, while others may have only one designated home infusion company.

CONSIDERATIONS WHEN CHOOSING A FACTOR PRODUCT: INFUSION 1. Volume of the Factor VIII to be Infused: Different factor VIII products offer the same dose in different volumes to infuse. It may be easier to infuse a smaller volume. If the factor VIII product you are infusing is one that is a smaller volume, such as 2.5cc, it is very important to make sure the entire product is infused, leaving none of the medicine in the butterfly tubing. To insure this, you must flush the tubing with a small amount of saline into the vein, after infusing the factor. 2. Butterfly Infusion Sets: For convenience, all of the factor VIII products come packaged with a butterfly infusion set, except for Recombinate. For this product, infusion sets can be sent from the home care company separately. 3. Type of Diluent Mixed with Factor VIII Product: Refacto brand of factor VIII uses saline as its diluent to mix with the powdered factor. The other brands we mentioned in the table use sterile water. It is important to use the correct diluent when mixing factor to be infused.. 4. Peel Off Label: All of the factor VIII products mentioned, except for Refacto, have a peel off label on the bottle with the lot number and expiration date. This makes it convenient to put infusion information in a log. All of the Factor VIII products mentioned should be infused within three hours of reconstituting (mixing the diluent with the factor powder).

PARTICIPANT Q&A: Question: Is there an increased risk of inhibitor formation as you switch from product to product? Should this limit one s participation in the free trial offerings from companies/distributors? Answer: There is very little scientific data that supports the theory that switching products leads to development of inhibitors. There have been several anecdotal reports of this occurring, but so far there is no evidence to show this is related to switching products. It was noted that patients are frequently switched in emergency situations (hospital may have different product) as well as during the factor shortage a few years ago. Factor sample programs require a prescprition from a physician. Concerns about changing products should be reviewed on an individual basis between physician and patient Question: Is there increased risk of impotence with Advate? (Participant was told by two friends that they developed difficulty with erections while on the Advate trial, and this problem went away when they returned to their former products). Answer: This is not listed as a side effect on the prescribing insert for Advate. As a follow up, HTC staff presented this question to Baxter representatives who also were not aware of this side effect. Patients should call Baxter medical affairs department to inquire further or to report side effects. Question: What is the closest agent to Recombinate? Is it Refacto? Answer: Refacto is the least similar to Recombinate. Kogenate FS and Helixate FS are probably the most similar to Recombinate. Question: Is Recombinate going away? Answer: Baxter has not made any official announcements about discontinuing Recombinate. It is expected that distribution of Recombinate will eventually be reduced or eliminated, as Baxter has put time and resources into developing a 3 rd generation product, Advate. When/if this happens, Baxter is expected to provide notice to patients well in advance so they can consider other options.

PRODUCT INFORMATION FROM MANUFACTURERS Please visit the manufacturer websites for more information about factor products and services: Baxter (Advate & Recombinate) www.hemophiliagalaxy.com Bayer (Kogenate FS) www.bayerbiologicals.com Wyeth (ReFacto) www.hemophiliavillage.com ZLB Behring (Helixate FS) www.aventisbehring.com